U.S. Markets open in 6 hrs 42 mins

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
620.21-1.00 (-0.16%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close621.21
Open621.00
Bid0.00 x 1300
Ask0.00 x 1400
Day's Range614.55 - 627.46
52 Week Range271.37 - 664.64
Volume432,739
Avg. Volume1,243,234
Market Cap65.985B
Beta (5Y Monthly)0.55
PE Ratio (TTM)24.01
EPS (TTM)25.83
Earnings DateNov 03, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est673.84
  • Regeneron Announces Pricing of Public Offering of Senior Unsecured Notes
    PR Newswire

    Regeneron Announces Pricing of Public Offering of Senior Unsecured Notes

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the pricing of an underwritten offering of $1.250 billion aggregate principal amount of senior unsecured notes due 2030 (the "2030 notes") and $750 million aggregate principal amount of senior unsecured notes due 2050 (the "2050 notes" and, together with the 2030 notes, the "notes"). The 2030 notes will bear interest at 1.750% per annum and will mature on September 15, 2030. The 2050 notes will bear interest at 2.800% per annum and will mature on September 15, 2050. The issuance of the notes is expected to close on or around August 12, 2020, subject to customary closing conditions.

  • Moody's

    Regeneron Pharmaceuticals, Inc. -- Moody's assigns Baa3 issuer rating to Regeneron

    NOTE: On August 07, 2020, the press release was corrected as follows: In the debt list, the description under “Ratings assigned” was changed to “Issuer rating, Baa3.” Revised release follows. New York, August 05, 2020 -- Moody's Investors Service ("Moody's") assigned a Baa3 issuer rating to Regeneron Pharmaceuticals, Inc. ("Regeneron"). "Regeneron's investment grade rating reflects growing global scale, strong scientific expertise, and an extremely conservative balance sheet, with very low financial leverage helping to mitigate business risks," stated Michael Levesque, Senior Vice President.

  • Moody's

    Regeneron Pharmaceuticals, Inc. -- Moody's rates Regeneron's sr. notes Baa3; stable outlook

    Moody's Investors Service ("Moody's") assigned a Baa3 rating to the new senior unsecured notes of Regeneron Pharmaceuticals, Inc. ("Regeneron"). "Regeneron's investment grade rating reflects growing global scale, strong scientific expertise, and an extremely conservative balance sheet, with very low financial leverage helping to mitigate business risks," stated Michael Levesque, Senior Vice President.